Skip to main content
Equibles
TXG logo

TXG

10x Genomics, Inc.
$40.00 +0.99 (+2.54%) At close · Jul 6
Market Cap
$5.37B
Shares
126,956,189

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$40.00 Open$39.25 Day$37.93–40.56 52W$11.16–40.56 Avg vol 30d3.3M Short int22.1M · 17.4% float · 6.8d Short vol57% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 8
Equibles Rating blended score · not investment advice
Overall
Buy
Technical · trend & momentum Buy
◦ 50 / 200-day cross no cross
+ Price vs 200-day avg +97% above
+ Price vs 50-day avg +44% above
− RSI (14) 75 · overbought
+ MACD trend positive
+ 52-week position 98% · near high
Sentiment · smart money Bearish
◦ Trend (MA cross) 50d $28 › 200d $20 — 50d above 200d
− Institutional flow 7 of 332 funds reported for Jun 30 · net -12.7K sh shares · +2 new
− Insider flow Net -$1.5M over 90 days · 100% sells
− Short interest 17.41% of float · ▲ +34.0% MoM · 6.8 days cover
◦ Volume signal Volume near normal
+ Institution breadth 332 holders — near 3-yr high, broad support
Fundamentals Excellent
+ Revenue growth +68% Y/Y
+ Gross margin 181%, contracting
+ EPS growth +77% Y/Y
+ Free cash flow $130.1M
+ Balance sheet net cash $314.3M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
Next earnings call
Aug 6, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 8, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Guidance & track record
      Latest guidance · from the 8-K filed May 7, 2026
      Revenue · full year 2026 Initiated $600M – $625M
      prior FY $642.82M midpoint −4.7% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 1 · 4
      50 / 200-day cross
      no cross Neutral
      Price vs 200-day avg
      +97% above Bullish
      Price vs 50-day avg
      +44% above Bullish
      RSI (14)
      75 · overbought Bearish
      MACD trend
      positive Bullish
      52-week position
      98% · near high Bullish
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $28 › 200d $20 — 50d above 200d
      Institutional flow Distributing
      7 of 332 funds reported for Jun 30 · net -12.7K sh shares · +2 new
      Insider flow Distributing
      Net -$1.5M over 90 days · 100% sells
      Short interest Rising
      17.41% of float · ▲ +34.0% MoM · 6.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      332 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $11 Now $40 · 98% 52-wk high $41
      vs 200-day avg +97% vs 50-day avg +44%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Gross margin 70% Q1 2026 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Health Information Services — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      TXG
      10x Genomics, Inc.
      this stock
      		$5.37B +145.2% +68.1% — 17.4%
      VEEV
      Veeva Systems Inc
      		 $31.57B -14.0% +28.1% 34.5 4.6%
      PMDIY
      Pro Medicus Ltd./ADR
      		 $15.67B -9.4% — — 0.0%
      BTSG
      BrightSpring Health Services, Inc.
      		 $13.68B +88.4% -0.4% 50.4 4.8%
      TEM
      Tempus AI, Inc.
      		 $11.21B +2.8% +65.8% — 21.2%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      334
      % held
      94.0%
      Reported
      7 of 332
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      288
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      22.1M
      Days to cover
      6.8d
      Change
      +5.6M sh
      View
      Short Volume
      Short vol %
      57%
      As of
      Jul 7, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      7.1K
      Value
      $205.6K
      As of
      Jun 12, 2026
      View
      Off-Exchange
      Off-exchange %
      44.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$1.5M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $642.8M
      Net income (FY)
      $-43.5M
      EPS diluted
      $-0.35
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 8, 2026
      This year
      7
      View
      Proposed Sales
      Value
      $232.7K
      Shares
      9.4K
      Filed
      May 22, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 13, 2026
      View
      Investor Relations
      Latest news
      10x Genomics and Cleveland Clinic…
      Published
      Jun 17, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      TXG +8.8% +19.4% +95.5% +4.3% +145.3%
      SPY +3.1% -0.8% +8.2% +0.6% +10.2%
      vs SPY +5.8% +20.2% +87.3% +3.7% +135.1%
      Key facts CIK 1770787 CUSIP 88025U109 13F (30d) 29 filings 10 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)